Correlation and clinical predictive value of IL-6, GP73, and CK-18 fragments with the clinical characteristics of simple liver cysts

doi:10.3877/cma.j.issn.2095-2015.2025.05.012

Abstract

Abstract:

Objective

To explore the correlation between interleukin 6 (IL-6), Golgi glycoprotein 73 (GP73), and cytokeratin 18 (CK-18) fragments and the clinical characteristics of simple hepatic cysts (SHC), and to analyze their predictive value for recurrence.

Methods

A retrospective analysis was conducted on the clinical data of 180 patients with SHC. The differences in IL-6, GP73, and CK18-M30 among SHC patients with different clinical characteristics were compared, and multivariate logistic regression analysis, multivariate Cox regression analysis, and receiver operating characteristic curve (ROC) analysis were conducted.

Results

There were statistically significant differences in IL-6, GP73, and CK18-M30 levels in the pre-treatment cystic fluid and peripheral blood among patients of different ages, hepatic cyst diameter, and disease severity (P<0.05). There were statistically significant differences in the severity of the disease and the levels of IL-6, GP73, and CK18-M30 in peripheral blood between those who were effective and those who were ineffective in SHC treatment (P<0.05). Multivariate logistic regression analysis showed that severe SHC and postoperative peripheral blood IL-6, GP73, and CK18-M30 levels were independent risk factors for ineffective treatment of SHC patients after percutaneous puncture and drainage sclerotherapy under ultrasound localization (P<0.05). There were statistically significant differences in the severity of disease, cyst diameter, and peripheral blood IL-6, GP73, and CK18-M30 levels after treatment between SHC relapse and non-relapse patients after treatment (P<0.05). Multivariate Cox regression analysis showed that large cysts (diameter≥10 cm) and postoperative peripheral blood IL-6, GP73, and CK18-M30 levels were independent risk factors for recurrence in SHC patients undergoing percutaneous puncture and drainage sclerotherapy under ultrasound localization (P<0.05). The ROC curve analysis showed that IL-6, GP73, and CK18-M30 in peripheral blood after treatment could predict the recurrence of SHC patients (P<0.05).

Conclusion

There are statistically significant differences in IL-6, GP73, and CK18-M30 levels in the cystic fluid of patients with different clinical characteristics of SHC. After treatment, peripheral blood IL-6, GP73, and CK18-M30 levels can predict patient recurrence.

Key words: Simple hepatic cyst, Inflammatory factors, Cytokeratin-18 fragment, Predictive value

Liguan Liu, Yan Yan, Huiling Chen, Jinpiao Wu, Zhijie Huang, Tao Xu, Yongfei Li, Qiaoxia Ye. Correlation and clinical predictive value of IL-6, GP73, and CK-18 fragments with the clinical characteristics of simple liver cysts[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(05): 486-491.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.05.012

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I05/486

Figures/Tables 7

References 21

[1]	吴少平. 单纯性肝囊肿的患病率调查与危险因素分析[D]. 中国人民解放军海军军医大学, 2020.
[2]	Cass DL. Fetal abdominal tumors and cysts[J]. Transl Pediatr, 2021, 10(5): 1530-1541.
[3]	Miyagawa K, Nakano Y, Yoneda A, et al. Hepatic Cyst Infection Following Recurrent Biliary Obstruction in Polycystic Liver Disease [J]. J UOEH, 2022, 44(4): 353-358.
[4]	郭志唐, 龙奎, 王琳, 等. 腹腔镜下肝囊肿剥除术在单纯性肝囊肿治疗中的应用[J]. 肝胆胰外科杂志, 2024, 36(7): 422-425.
[5]	Shimizu T, Yoshioka M, Kaneya Y, et al. Management of Simple Hepatic Cyst[J]. J Nippon Med Sch, 2022, 89(1): 2-8.
[6]	刘红, 王耀, 胡于凤, 等. 介入穿刺引流与外科手术引流治疗肝囊肿患者疗效分析[J]. 实用肝脏病杂志, 2021, 24(5): 745-748.
[7]	Kumar A, Zendel A, Batre Satres M, et al. Radiologic Reporting of Simple Hepatic Cyst Versus Biliary Cystadenoma May Lead to Unnecessary Surgery[J]. Am Surg, 2023, 89(5): 1392-1395.
[8]	Ferrer Inaebnit E, Molina Romero FX, Segura Sampedro JJ, et al. A review of the diagnosis and management of liver hydatid cyst[J]. Rev Esp Enferm Dig, 2022, 114(1): 35-41.
[9]	陈亚进, 张磊. 2014年美国胃肠病学会《肝脏局灶性病变诊断和管理指南》解读[J]. 中国实用外科杂志, 2015, 35(1): 20-24.
[10]	王宝恩, 张定凤. 《现代肝脏病学》[M]. 北京: 科学出版社, 2003: 106-108.
[11]	袁洁, 韩国宏. 《2022年欧洲肝病学会临床实践指南:囊性肝病的管理》摘译[J]. 胃肠病学, 2023, 28(1): 31-35.
[12]	Eso Y, Shimizu H, Takai A, et al. Ultrasound-guided polidocanol foam sclerotherapy for symptomatic giant hepatic cyst: a single- center experience[J]. Hepatol Res, 2022, 52(6): 557-565.
[13]	Zhang JW, Peng C, Ye YS, et al. Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report[J]. World J Gastrointest Surg, 2020, 12(12): 549-554.
[14]	佘政荣, 张耀明. 先天性肝囊肿的治疗进展[J]. 肝脏, 2024, 29(10): 1281-1285.
[15]	张麒, 马臻. 丙型肝炎肝纤维化进展影响因素及标志物研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(1): 1-6.
[16]	Pang BY, Leng Y, Wang X, et al. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma[J]. Ann Med, 2023, 55(1): 42-61.
[17]	朱梦莹, 常家宝, 傅熙玲, 等. 药物性肝损伤患者血清CK18-M30、CK18-M65水平及临床意义[J]. 江苏医药, 2023, 49(3): 268-271.
[18]	陈敏胜. 腹腔镜下开窗引流术治疗肝囊肿患者的疗效[J/OL]. 中华消化病与影像杂志(电子版), 2022, 12(5): 310-311.
[19]	严彦, 颜燕燕, 刘理冠. 经皮穿刺置管无水乙醇冲洗联合聚桂醇泡沫治疗单纯性肝囊肿的疗效及对血炎症因子及CK-18片段的影响[J]. 中西医结合肝病杂志, 2023, 33(3): 224-226.
[20]	李玮健, 刘昕, 舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究[J]. 实用肝脏病杂志, 2024, 27(3): 450-453.
[21]	Riedesel EL, Richer EJ, Taylor SD, et al. Pediatric hepatic cystic lesions: dierential diagnosis and mltimodality imaging approach[J]. Radiographics, 2022, 42(5): 1514-1531.

临床特点	IL-6(mg/L)		t	P	GP73(mg/L)		t	P	CK18-M30(ng/L)		t	P
临床特点	囊液	外周血	t	P	囊液	外周血	t	P	囊液	外周血	t	P
性别
男(n=96)	0.54±0.08	0.42±0.05	0.384	0.702	90.21±6.11	82.48±5.27	0.967	0.338	91.14±7.21	82.04±4.89	0.630	0.531
女(n=84)	0.55±0.12	0.44±0.06	1.408	0.164	91.78±6.46	83.16±5.44	0.491	0.625	92.34±7.54	81.75±4.52	0.237	0.813
年龄
<50岁(n=60)	0.52±0.08	0.46±0.07	5.820	<0.001	89.94±6.45	84.32±5.13	2.192	0.032	90.05±6.76	75.37±4.38	2.948	0.005
≥50岁(n=120)	0.68±0.13	0.62±0.11	5.919	<0.001	93.78±7.12	87.71±5.82	2.209	0.031	95.37±7.21	78.42±5.11	2.281	0.026
囊肿直径大小
<10 cm (n=75)	0.49±0.05	0.42±0.04	9.913	<0.001	90.89±6.04	82.26±4.85	3.595	0.001	91.48±6.21	78.47±5.11	2.652	0.010
≥10 cm (n=105)	0.72±0.12	0.63±0.07	13.490	<0.001	96.89±6.89	85.71±5.21	2.602	0.012	96.04±7.11	83.06±5.24	3.380	0.001
疾病严重程度
轻微(n=138)	0.53±0.07	0.34±0.03	6.404	<0.001	91.48±6.14	81.75±4.37	2.493	0.016	91.73±6.21	82.77±4.83	2.323	0.024
严重(n=42)	0.69±0.12	0.48±0.05	12.928	<0.001	95.78±7.22	84.92±4.22	2.395	0.020	95.82±7.43	86.39±5.21	2.412	0.019
治疗效果
无效(n=30)	0.64±0.11	0.55±0.08	0.913	0.365	94.34±6.78	88.42±7.11	0.719	0.475	93.16±6.28	85.56±4.38	0.194	0.847
有效(n=150)	0.61±0.14	0.53±0.09	0.652	0.517	93.13±6.25	85.71±6.82	1.139	0.259	92.84±6.45	84.12±4.11	1.001	0.321
复发情况
复发(n=45)	0.68±0.17	0.52±0.12	1.491	0.143	96.32±6.44	84.17±5.44	1.109	0.273	93.78±6.32	85.21±5.86	0.458	0.649
未复发(n=135)	0.62±0.11	0.48±0.07	1.480	0.145	94.13±6.38	83.38±5.29	0.480	0.634	92.89±6.29	84.47±5.56	0.424	0.673

临床特点	IL-6(mg/L)		t	P	GP73(mg/L)		t	P	CK18-M30(ng/L)		t	P
临床特点	囊液	外周血	t	P	囊液	外周血	t	P	囊液	外周血	t	P
性别
男(n=96)	0.54±0.08	0.42±0.05	0.384	0.702	90.21±6.11	82.48±5.27	0.967	0.338	91.14±7.21	82.04±4.89	0.630	0.531
女(n=84)	0.55±0.12	0.44±0.06	1.408	0.164	91.78±6.46	83.16±5.44	0.491	0.625	92.34±7.54	81.75±4.52	0.237	0.813
年龄
<50岁(n=60)	0.52±0.08	0.46±0.07	5.820	<0.001	89.94±6.45	84.32±5.13	2.192	0.032	90.05±6.76	75.37±4.38	2.948	0.005
≥50岁(n=120)	0.68±0.13	0.62±0.11	5.919	<0.001	93.78±7.12	87.71±5.82	2.209	0.031	95.37±7.21	78.42±5.11	2.281	0.026
囊肿直径大小
<10 cm (n=75)	0.49±0.05	0.42±0.04	9.913	<0.001	90.89±6.04	82.26±4.85	3.595	0.001	91.48±6.21	78.47±5.11	2.652	0.010
≥10 cm (n=105)	0.72±0.12	0.63±0.07	13.490	<0.001	96.89±6.89	85.71±5.21	2.602	0.012	96.04±7.11	83.06±5.24	3.380	0.001
疾病严重程度
轻微(n=138)	0.53±0.07	0.34±0.03	6.404	<0.001	91.48±6.14	81.75±4.37	2.493	0.016	91.73±6.21	82.77±4.83	2.323	0.024
严重(n=42)	0.69±0.12	0.48±0.05	12.928	<0.001	95.78±7.22	84.92±4.22	2.395	0.020	95.82±7.43	86.39±5.21	2.412	0.019
治疗效果
无效(n=30)	0.64±0.11	0.55±0.08	0.913	0.365	94.34±6.78	88.42±7.11	0.719	0.475	93.16±6.28	85.56±4.38	0.194	0.847
有效(n=150)	0.61±0.14	0.53±0.09	0.652	0.517	93.13±6.25	85.71±6.82	1.139	0.259	92.84±6.45	84.12±4.11	1.001	0.321
复发情况
复发(n=45)	0.68±0.17	0.52±0.12	1.491	0.143	96.32±6.44	84.17±5.44	1.109	0.273	93.78±6.32	85.21±5.86	0.458	0.649
未复发(n=135)	0.62±0.11	0.48±0.07	1.480	0.145	94.13±6.38	83.38±5.29	0.480	0.634	92.89±6.29	84.47±5.56	0.424	0.673

组别	例数	性别(例)		年龄(例)		疾病严重程度(例)
组别	例数	男(n=96)	女(n=84)	<50岁(n=60)	≥50岁(n=120)	轻微(n=138)	严重(n=42)
有效	150	78	72	45	105	126	24
无效	30	18	12	15	15	12	18
χ²		0.214		1.500		9.019
P		0.643		0.221		0.003
组别	例数	囊肿直径大小(例)		IL-6(mg/L,±s)	GP73(mg/L,±s)	CK18-M30(ng/L,±s)
组别	例数	<10 cm(n=75)	≥10 cm(n=105)	IL-6(mg/L,±s)	GP73(mg/L,±s)	CK18-M30(ng/L,±s)
有效	150	60	90	0.62±0.11	107.71±8.77	96.46±15.41
无效	30	15	15	0.87±0.16	134.84±10.78	115.89±16.38
χ²/t		0.343		4.707	7.464	3.455
P		0.558		<0.001	<0.001	0.001

组别	例数	性别(例)		年龄(例)		疾病严重程度(例)
组别	例数	男(n=96)	女(n=84)	<50岁(n=60)	≥50岁(n=120)	轻微(n=138)	严重(n=42)
有效	150	78	72	45	105	126	24
无效	30	18	12	15	15	12	18
χ²		0.214		1.500		9.019
P		0.643		0.221		0.003
组别	例数	囊肿直径大小(例)		IL-6(mg/L,±s)	GP73(mg/L,±s)	CK18-M30(ng/L,±s)
组别	例数	<10 cm(n=75)	≥10 cm(n=105)	IL-6(mg/L,±s)	GP73(mg/L,±s)	CK18-M30(ng/L,±s)
有效	150	60	90	0.62±0.11	107.71±8.77	96.46±15.41
无效	30	15	15	0.87±0.16	134.84±10.78	115.89±16.38
χ²/t		0.343		4.707	7.464	3.455
P		0.558		<0.001	<0.001	0.001

因素	β	SE	Wald χ²	P	OR(95% CI)
疾病严重程度	2.132	0.871	5.982	0.012	1.629(1.124~2.544)
IL-6	0.932	0.311	8.981	<0.001	2.540(1.894~3.721)
GP73	0.176	0.052	11.136	0.001	1.194(1.073~1.331)
CK18-M30	0.568	0.192	9.118	0.004	1.771(1.224~2.562)

Please choose a citation manager

Content to export